CompletedNo phase
MINDS Imaging Ancillary Study
Key facts
- Who runs it
- University of Pittsburgh
- Where
- Ann Arbor, Atlanta, Boston, Charleston, Cincinnati, Houston, Indianapolis, Milwaukee, New York, Philadelphia, Pittsburgh, and Salt Lake City, United StatesSee the 12 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 195 people enrolled
- Started
- 27 May 2021
- Ended
- 31 May 2025
- Type of study
- Observational
- Treatments tested
- MRI
- Record updated
- 31 October 2025
Who can take part
- Age
- 18 years to 30 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Participation in and completion of MINDS parent study procedures. The inclusion criteria for the MINDS parent study consists of ACHD patients aged 18 - 30 years with moderate and severely complex CHD
Who cannot take part
- Implantable device (i.e., pacemaker; defibrillator; ferromagnetic aneurysm clips; cochlear implant; gastric reflux device; internal insulin pump; pacing leads; neurostimulation system) that cannot be cleared for scanning at 3T
- Braces or orthodontic appliances that cannot be removed prior to scanning and/or cannot be cleared for scanning at 3T
- Individuals with mild complexity lesions
- Individuals with MRI contraindications will be excluded from study participation. Contraindications include, but are not limited, to:
- Pregnancy or breast feeding
- Claustrophobia or inability to lie still for an extended period
- Foreign body (i.e., metallic splinter in the eye; bullet or grenade fragments)
- Individuals who are unable to participate in the informed consent process or complete the study questionnaire will also be excluded from participation
Where in United States
Also in 1 other country, 1 site
- University of MichiganAnn Arbor, United StatesNo longer taking part
- Emory UniversityAtlanta, United StatesNo longer taking part
- Boston Children's HospitalBoston, United StatesNo longer taking part
- Medical University of South CarolinaCharleston, United StatesNo longer taking part
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesNo longer taking part
- Baylor College of MedicineHouston, United StatesNo longer taking part
- Indiana UniversityIndianapolis, United StatesNo longer taking part
- Medical College of WisconsinMilwaukee, United StatesNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesNo longer taking part
- University of UtahSalt Lake City, United StatesNo longer taking part
About the trial
What the trial wants to find out
This study is an ancillary study to the NHLBI-funded Pediatric Heart Network (PHN) "Multi-Institutional Neurocognitive Discovery Study" (MINDS) in Adult Congenital Heart Disease (ACHD). The MINDS-ACHD" study will recruit 500 complex CHD patients between18-30 years old. The investigators propose to quantitate multi-modal neuroimaging biomarkers (brain injury, structure and physiology) which are not only important components of brain and cognitive reserve but can be predictive of neurocognitive decline and early onset of dementia in the aging non-CHD population.
Treatments tested
- MRI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 31 October 2025